While stimulating the subthalamic nucleus (STN) generally has been the therapy of choice, new research published in the June 20, 2012, issue of Neurology®, the medical journal of the American Academy of Neurology, challenges that preferred status, finding that stimulating the internal globus pallidus (GPi) may provide some long-term advantages.
The subthalamic nucleus has been regarded as the preferred target since 2002, when the Food and Drug Administration approved the therapy for Parkinson’s disease. Many physicians made this therapeutic choice because stimulation of the subthalamic nucleus often enabled patients to reduce their drugs, such as levodopa; the choice of target was left to doctors because no major clinical trial had shown that one target provides better results than the other.
The largest randomized trial, published in 2010, found “motor” outcomes – movement control – fared equally, regardless of target. That study and others also showed that while stimulation can improve motor skills, it does not stop cognitive, mood or behavioral declines.
The new study, based on outcomes in 159 patients from the 2010 trial, challenges the preferred targeting, finding that stimulating the internal globus pallidus may provide long-term advantages in both motor skills and cognitive function.
In his editorial, Tagliati says these and other findings warrant more research to answer questions such as: “Is it important or even desirable to reduce medications over the long term? Do medication and stimulation have a complementary or alternative role? Is GPi stimulation more compatible with long-term medical therapy? Is chronic STN stimulation interfering with dopaminergic stimulation?”
“If the art of making medical decisions reflects a continuous struggle between evidence- and preference-based practices, this study will inject more reliable evidence in delicate long-term decisions, based until now almost exclusively on the preference and personal experience of the DBS provider,” he concludes.
Citation: Neurology: “Turning Tables: Should GPi become the preferred DBS target for Parkinson’s Disease?” (editorial), published online at 4 p.m. Eastern time June 20, 2012, in print July 3, 2012.Media Contact: Sandy Van
Sandy Van | Cedars-Sinai News
Nanoparticles as a Solution against Antibiotic Resistance?
15.12.2017 | Friedrich-Schiller-Universität Jena
Plasmonic biosensors enable development of new easy-to-use health tests
14.12.2017 | Aalto University
11.12.2017 | Event News
08.12.2017 | Event News
07.12.2017 | Event News
15.12.2017 | Power and Electrical Engineering
15.12.2017 | Materials Sciences
15.12.2017 | Life Sciences